Advaxis, Inc. (NASDAQ:ADXS)
Industry: Healthcare

OFF LIST - 685 consecutive market days: OFF LIST as of 09/13/2013 Through 11/14/2016

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) which is phase II clinical trial for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product developed using whole-exome sequencing of a patient's tumor to identify neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

Current Quote*
Last: $0.667
Change: -0.038
Book: $1.029
Volume: 877,732

As Of: 05/29 13:04 ET
*Quotes delayed by 20min.

Graphs for ADXS


3 Month Graph


6 Month Graph


1 Year Graph